Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;3(4):171-84.
doi: 10.1177/1758834011408636.

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

Martin Sattler  1 , Mamatha M Reddy, Rifat Hasina, Tara Gangadhar, Ravi Salgia
Affiliations

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

Martin Sattler et al. Ther Adv Med Oncol. 2011 Jul.

Abstract

Hepatocyte growth factor receptor (HGFR), the product of the MET gene, plays an important role in normal cellular function and oncogenesis. In cancer, HGFR has been implicated in cellular proliferation, cell survival, invasion, cell motility, metastasis and angiogenesis. Activation of HGFR can occur through binding to its ligand, hepatocyte growth factor (HGF), overexpression/amplification, mutation, and/or decreased degradation. Amplification of HGFR can occur de novo or in resistance to therapy. Mutations of HGFR have been described in the tyrosine kinase domain, juxtamembrane domain, or semaphorin domain in a number of tumors. These mutations appear to have gain of function, and also reflect differential sensitivity to therapeutic inhibition. There have been various drugs developed to target HGFR, including antibodies to HGFR/HGF, small-molecule inhibitors against the tyrosine kinase domain of HGFR and downstream targets. Different HGFR inhibitors are currently in clinical trials in lung cancer and a number of solid tumors. Several phase I trials have already been completed, and two specific trials have been reported combining HGFR with epidermal growth factor receptor (EGFR) inhibition in non-small cell lung cancer. In particular, trials involving MetMAb and ARQ197 (tivantinib) have gained interest. Ultimately, as individualized therapies become a reality for cancers, HGFR will be an important molecular target.

Keywords: MET; hepatocyte growth factor; kinase inhibitors; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abella J.V., Peschard P., Naujokas M.A., Lin T., Saucier C., Urbe S., et al. (2005) Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25: 9632–9645 - PMC - PubMed
    1. Banerji L., Sattler M. (2004) Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias. Expert Opin Ther Targets 8: 221–239 - PubMed
    1. Bardelli A., Longati P., Gramaglia D., Stella M.C., Comoglio P.M. (1997) Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 15: 3103–3111 - PubMed
    1. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932–20937 - PMC - PubMed
    1. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768–771 - PubMed